Results
Corona Remedies FY26 Net Profit Rises 33.4% to ₹185.12 Crore
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting revenue growth of 17.3% and PAT growth of 33.4%.
Recommended a final dividend of ₹10
